FIG 1. Quenching of QS21 haemolytic activity with cholesterol



FIG. 2. Hydrolysis of QS21 in alkaline aqueous medium



FIG 3. Anti-gp120 CTL activity generated by QS21 as adjuvant



FIG 4. Anti-gp120 CTL activity generated by QS21 and cholesterol containing liposome as adjuvant



FIG 5. Anti-gD antibodies in AGM



FIG 6. Antigen specific proliferation was measured by stimulation in vitro with gD coupled to microbeads, and expressed as CPM of 3H-TdR incorporated.



FIG 7. IL-2 production of cells after gD vaccination and restimulation in vitro.



FIG 8. Interferon gamma production of cells after gD vaccination and restimulation in vitro



FIG 9. RSV neutralisation titres and anti FG ELISA titres after vaccination





FIG 10. Comparison of QS21-SUV containing formulations with Alum formulation Kinetics of the anti-HBs response (post I/II)





Figure 10 (continued)



FIG 11. Comparison of QS21-SUV containing formulations with Alum formulation Isotypic profile (post II) anti-HBs response



	% IgG1	% IgG2a	% IgG2b
S,L* /Alum	93	3	3
S,L* /alum/MPL/QS21-SUV	44	46	10
S,L* /alum / QS21-SUV	44	47	9
S,L* /MPL /QS21-SUV	27	55	18